Renalytix PLC (RNLX): EV/EBITDA Multiple

Public company logo of Renalytix, plc (RNLX)

The digital renal diagnostics market is currently expanding rapidly due to high demand for early risk detection. The price indicator on the chart for Renalytix Plc (RNLX), which stands at , complements the business data. Renalytix Plc is developing a network of AI tools for nephrologists that enable the prediction of organ failure. A cloud-based biomarker analysis service ensures seamless system scaling with minimal costs per new patient.

Renalytix Plc - RNLX Enterprise Value to Operating Income Before Depreciation (period 07/04/2022 - 11/14/2026)

RNLX (Renalytix, plc): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Renalytix|RNLX - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Capitalization Renalytix AI|RNLX - Company Buyout Price
- issuer book value statistics:
Book Value per Share Renalytix|RNLX - Accounting Capitalization|Market Value to Book Value Ratio renalytix.com|RNLX - Total Business Assets
- company liabilities and liquidity data:
Total Debt to Capital Renalytix Plc|RNLX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Renalytix|RNLX - Company Cumulative Debt|Debt to Book Capitalization Ratio Renalytix PLC|RNLX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Renalytix|Quick Liquidity renalytix.com
- financial results and valuation multiples details:
RNLX - Company Profit|Projected Future Earnings Renalytix Plc|RNLX - P/E Multiple|Future Price to Earnings Renalytix|RNLX - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Renalytix, plc|RNLX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Renalytix|RNLX - Earnings per share for the last four quarters|Quarterly EPS earnings growth renalytix.com|RNLX - Expected net earnings per share growth this year|Expected earnings per share growth for next year Renalytix Plc
- sales and revenue indicators:
RNLX - Company Sales Volume|Company Future Sales Volume Renalytix PLC|RNLX - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Renalytix
Initial company analysis:RNLX (Renalytix Plc)
Product sample of Renalytix AI

This indicator compares the total enterprise value, including net debt, to its earnings before interest, taxes, depreciation, and amortization. The EV/EBITDA ratio trend for Renalytix Plc (RNLX) on this chart allows investors to determine the degree of asset overvaluation relative to their ability to generate cash flow. For Renalytix Plc (RNLX), this calculation is critical when assessing the impact of expanded Medicare coverage on the capitalization of AI diagnostics.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Travere Corp TVTX|EV/EBITDA Multiple Ardelyx, Inc. ARDX|ProKidney Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Akebia Therapeutics, Inc. AKBA|TVRD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation DMAC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unicycive Therapeutics, Inc.|Enterprise Value to Operating Income Before Depreciation RMTI (Rockwell Medical)|EV/EBITDA Multiple CVKD|CDT - Company Value to EBITDA|Calliditas Therapeutics AB - Enterprise Value to EBITDA Ratio|zyversa.com (ZVSA) - Company Value to EBITDA